Jeito, a private equity firm, and UMPCE, a University of Pittsburgh Medical Center Enterprise, led a €75m Series B round in SparingVision, biotech company, with participation from Ysios Capital, 4Bio, Bpifrance, and Foundation Fighting Blindness. “SparingVision is one of Jeito's first investments and we are thrilled today to confirm our support to the Company’s strategy for the best of patients. Key milestones have been achieved and the Company will be able to accelerate its two lead assets towards clinical proof of concept. Our new investment in SparingVision illustrates perfectly Jeito Capital's mission to build market leaders with global reach to bring ground-breaking therapies to patients with high unmet needs. We invest in continuity, supporting promising biotech companies to help them reach the market and thus the patients. We look forward to continuing supporting SparingVision’s future successes to contribute in building a global leader in genomics for ocular Diseases," Rafaèle Tordjman, Jeito Founder and CEO.